With 0.7 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.45 million shares. The 52-week range on ZYME shows that it touched its highest point at $17.70 and its lowest point at $7.97 during that stretch. It currently has a 1-year price target of $20.44. Beta for the stock currently stands at 1.16.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZYME was down-trending over the past week, with a drop of -6.04%, but this was down by -12.67% over a month. Three-month performance dropped to -11.58% while six-month performance rose 8.79%. The stock gained 6.16% in the past year, while it has lost -12.91% so far this year. A look at the trailing 12-month EPS for ZYME yields -1.51 with Next year EPS estimates of -1.75. For the next quarter, that number is -0.10. This implies an EPS growth rate of 16.11% for this year and -21.46% for next year. EPS is expected to grow by 12.51% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -6.52%.
Float and Shares Shorts:
At present, 69.58 million ZYME shares are outstanding with a float of 66.62 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZYME since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.29776 being high and -$1.80597 being low. For ZYME, this leads to a yearly average estimate of -$1.44296. Based on analyst estimates, the high estimate for the next quarter is -$0.23 and the low estimate is -$0.59. The average estimate for the next quarter is thus -$0.44.
Summary of Insider Activity:
Insiders traded ZYME stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
